We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+4.23%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.4B
AUM Growth
+$2.4B
Cap. Flow
+$169M
Cap. Flow %
7.05%
Top 10 Hldgs %
44.25%
Holding
367
New
126
Increased
77
Reduced
66
Closed
85

Top Buys

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$94.4M
2
IWM icon
iShares Russell 2000 ETF
IWM
+$24M
3
AGN
Allergan plc
AGN
+$13.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$11.9M
5
MBLY
Mobileye N.V.
MBLY
+$8.8M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$42.1M
2
GILD icon
Gilead Sciences
GILD
+$11.5M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$11.1M
4
A icon
Agilent Technologies
A
+$6.68M
5
ADVM
Adverum Biotechnologies
ADVM
+$3.71M

Sector Composition

Rank Sector Weight
1 Healthcare 9.36%
2 Technology 0.55%
3 Energy 0.39%
4 Industrials 0.16%
5 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SCON
276
PUT
DELISTED
Superconductor Technologies Inc.
SCON
– –
0
– –
A icon
277
Agilent Technologies
A
$39.7B
– –
-165,008
Closed -$6.68M
ACAD icon
278
CALL
Acadia Pharmaceuticals
ACAD
$4.45B
– –
-28,364
Closed -$90.1K
ACAD icon
279
Acadia Pharmaceuticals
ACAD
$4.45B
– –
-864,437
Closed -$27.4K
ACAD icon
280
PUT
Acadia Pharmaceuticals
ACAD
$4.45B
– –
-973
Closed -$3.09K
ACHV icon
281
Achieve Life Sciences
ACHV
$634M
– –
-210
Closed -$1.06K
AKTX
282
Akari Therapeutics
AKTX
$14.8M
– –
-67
Closed -$2.59K
ALKS icon
283
Alkermes
ALKS
$8.47B
– –
-13,827
Closed -$945K
ALT icon
284
CALL
Altimmune
ALT
$581M
– –
-4
Closed -$221
AMGN icon
285
CALL
Amgen
AMGN
$212B
– –
-580
Closed -$9.24K
AMT icon
286
CALL
American Tower
AMT
$79.9B
– –
-462
Closed -$4.57K
AMT icon
287
PUT
American Tower
AMT
$79.9B
– –
-25
Closed -$247
AZN icon
288
CALL
AstraZeneca
AZN
$267B
– –
-2,503
Closed -$17.6K
AZN icon
289
AstraZeneca
AZN
$267B
– –
-192,055
Closed -$13.5K
AZN icon
290
PUT
AstraZeneca
AZN
$267B
– –
-4,338
Closed -$30.5K
BMRN icon
291
BioMarin Pharmaceuticals
BMRN
$12B
– –
-5,039
Closed -$534K
BMY icon
292
PUT
Bristol-Myers Squibb
BMY
$130B
– –
-2,359
Closed -$13.9K
CARM
293
DELISTED
Carisma Therapeutics
CARM
– –
-34,874
Closed -$8.29K
CASI
294
DELISTED
CASI Pharmaceuticals
CASI
– –
-83,609
Closed -$1.11K
CVM icon
295
CEL-SCI Corp
CVM
$21M
– –
-17
Closed -$8
ESPR
296
CALL
DELISTED
Esperion Therapeutics
ESPR
– –
-206
Closed -$833
EXAS
297
PUT
DELISTED
Exact Sciences
EXAS
– –
-1,072
Closed -$2.94K
EXEL icon
298
Exelixis
EXEL
$14.2B
– –
-45,622
Closed -$106K
FOLD
299
DELISTED
Amicus Therapeutics
FOLD
– –
-246,697
Closed -$2.17M
GALT icon
300
Galectin Therapeutics
GALT
$223M
– –
-15,842
Closed -$55
10 11
12
13 14

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2015 Portfolio in Review

As of Q1 2015, Sabby Management held 367 positions worth $2.4B, up 75,773% from $3.17M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management deployed $169M of net new capital in Q1 2015, opening 126 new positions and adding to 77 existing holdings. Its largest new stake was Tempest Therapeutics: 709 shares worth $4.69M.

By sector, the portfolio is most concentrated in Healthcare at 9.4% of assets, up from 9.2% a quarter earlier, followed by Technology and Energy.

On the sell side, the largest reduction was Achillion Pharmaceuticals, an estimated $11.1M trimmed.

  • Sabby Management's largest Q1 2015 buy was Tempest Therapeutics: 709 shares worth $4.69M.
  • Sabby Management added most to Allergan plc in Q1 2015, an estimated $13.8M increase.
  • Sabby Management's biggest Q1 2015 reduction was Achillion Pharmaceuticals, cutting an estimated $11.1M.
  • Sabby Management fully exited Pfizer in Q1 2015, selling an estimated $42.1M.
  • Sabby Management's ten largest holdings make up 44% of its $2.4B portfolio in Q1 2015.
  • Sabby Management opened 126 new positions and closed 85 in Q1 2015.
  • Sabby Management's portfolio value rose 75,773% quarter-over-quarter to $2.4B.

Based on Sabby Management's 13F filing for Q1 2015, filed 15 May 2015.